文献库搜索 | GeneLibs

Elia(JL),Hill(J),Heer(CD),Smolev(S),Sykes(... bioRxiv 2026-07-09

...BRCA2-deficient tumor cells. CB1954 forms DNA interstrand crosslinks independent of HR status, but selectively induces D...

Xu(J),Sun(J),Tang(J),Huai(W),Gao(Y),Yao(R)... Clin Chim Acta 2026-07-07

...BRCA2 (35%), PALB2 (22%), BRCA1 (20%), and Lynch syndrome genes PMS2 (13%) and MSH6 (6%). Most variants were loss-of-fun...

Alvarez-Palacios(O),Ojeda-Campos(L),Rodríg... Rare Tumors None

...BRCA2 variant (c.1910-2A>T) along with additional likely pathogenic variants (CUX1, MED12L, POLR3B, PIK3CA). The disease...

Lemert(P),Chen(HZ),Shreenivas(A),Eaves(K),... JCO Oncol Adv 2026-04-00

...BRCA2, PMS2, SDHB, ATM, CHEK2). Universal germline testing identified a substantial number of patients with clinically v...

Chen(H),Wang(Y),Ding(Y),Qu(M),Gao(X) Int Urol Nephrol 2026-07-09

...BRCA2 mutations (especially biallelic loss) are the most robust predictors of platinum sensitivity, whereas the benefit ...

Taris(N),Amand(NDS),Hild(C),Mathelin(C),Ch... Cancer Genet 2026-07-06

...BRCA2 (n=4), PALB2 (n=2), ATM (n=2), and BRCA1 (n=1). The mean age at diagnosis was higher among variant carriers compar...

Torr(B),Mansour(L),Fierheller(CT),Hamill(M... NPJ Breast Cancer 2026-07-09

...BRCA2/PALB2) and 18.2% of gPVs in intermediate penetrance-BCSGs (CHEK2/ATM/RAD51C/RAD51D). Designing 'Ultra-simple' elig...

Lin(X),Li(R),Sun(C),Zhang(M),Wan(J),Li(Q) Gynecol Pelvic Med None

...BRCA2 mutation received initial treatment consisting of suboptimal cytoreductive surgery followed by first-line carbopla...

George(DJ),Kariburyo-Yay(F),Aggarwal(H),Te... Urol Oncol 2026-09-00

...BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, and RAD54L. Biomarker testing patterns and trea...

Iida(K),Tashiro(K),Urabe(F),Matsui(Y),Urab... Eur Urol Open Sci 2026-08-00

...BRCA2 (15% and 23%), and MYC (17% and 14%), with no statistically significant differences across histology and specimen ...